Ipamorelin
Ipamorelin is a synthetic peptide studied for its ability to stimulate growth hormone release through the ghrelin receptor. Researchers are especially interested in its selective hormone activity and possible effects on digestion, metabolism, and tissue recovery.
IPAMORELIN AT A GLANCE
WHAT IS IPAMORELIN?
Ipamorelin is a synthetic peptide made from five amino acids. It belongs to the growth hormone secretagogue family, a group of compounds that stimulate the body’s natural growth hormone-release pathway rather than acting as growth hormone themselves.
Ipamorelin was developed to produce a more selective growth hormone response than earlier compounds such as GHRP-2, GHRP-6, and Hexarelin. Early research found less activity involving ACTH and cortisol, although selectivity does not establish safety or guarantee that other hormonal effects cannot occur.
HOW DOES IPAMORELIN WORK?
Ipamorelin activates the growth hormone secretagogue receptor, also called the ghrelin receptor or GHS-R1a. These receptors are present in the hypothalamus and pituitary gland, where their activation encourages the release of stored growth hormone.
Ghrelin receptors are also found in parts of the digestive system. This has led researchers to examine whether Ipamorelin can influence stomach contractions and the movement of food through the digestive tract in addition to its endocrine effects.
Areas of Research
Ipamorelin research focuses primarily on growth hormone signaling, but its connection with the ghrelin receptor has also created interest in digestive and metabolic activity.
GROWTH HORMONE RELEASE
Examining how Ipamorelin stimulates the pituitary gland and how its response compares with other growth hormone secretagogues.
HORMONE SELECTIVITY
Studying whether Ipamorelin produces fewer effects involving ACTH, cortisol, and prolactin than GHRP-2, GHRP-6, or Hexarelin.
DIGESTIVE FUNCTION
Exploring stomach contractions, gastric emptying, and recovery from slowed digestive movement in experimental models.
METABOLISM AND RECOVERY
Investigating how growth hormone and ghrelin-receptor activity may influence glucose regulation, body composition, tissue maintenance, and recovery.
Research Highlights
Early laboratory and animal research identified Ipamorelin as a comparatively selective growth hormone secretagogue. Rodent studies also reported increased gastric movement, leading to human trials involving postoperative ileus. A randomized clinical study did not demonstrate a meaningful improvement in the primary recovery outcome, however, and safety concerns were reported. The FDA states that available evidence is insufficient to establish the safety of compounded Ipamorelin products and identifies potential risks involving immune reactions and peptide-related impurities.
WHAT IS IPAMORELIN MOST COMMONLY RESEARCHED FOR?
Ipamorelin is most commonly studied for growth hormone release. Researchers use it to examine pituitary responsiveness and determine whether selective ghrelin-receptor activation can stimulate growth hormone with fewer effects on other endocrine signals. Research involving muscle growth, performance, or recovery is less direct and should not be treated as established evidence of those outcomes.
HOW IS IPAMORELIN DIFFERENT FROM GHRP-2, GHRP-6, AND HEXARELIN?
All four compounds activate the ghrelin receptor and stimulate growth hormone release. Ipamorelin is generally distinguished by its more selective response, while GHRP-2, GHRP-6, and Hexarelin may produce broader effects involving cortisol, ACTH, prolactin, or appetite. Their potency, structure, and response patterns also differ, so research involving one should not automatically be applied to another.
WHAT MAKES IPAMORELIN UNIQUE?
Ipamorelin stands out because it was designed to separate growth hormone release from some of the broader endocrine activity associated with earlier secretagogues. Researchers have also examined its effects on digestive movement, giving it a research history that extends beyond pituitary signaling. Selectivity does not mean the compound is free from risks or unintended effects.
CAN IPAMORELIN BE RESEARCHED ALONGSIDE OTHER PEPTIDES?
Researchers may compare Ipamorelin with GHRP-2, GHRP-6, Hexarelin, or growth hormone-releasing hormone compounds such as CJC-1295. Studying multiple secretagogues together can change the strength and timing of the growth hormone response while making it harder to determine which compound produced an observed effect.
WHAT HAVE RESEARCHERS LEARNED ABOUT IPAMORELIN SO FAR?
Researchers have learned that Ipamorelin activates the ghrelin receptor and can stimulate growth hormone release with comparatively limited ACTH and cortisol activity in early experimental models. Studies have also identified effects on gastric contractions and emptying in animals, but human research involving postoperative digestive recovery did not confirm a clear clinical benefit.
IS RESEARCH ON IPAMORELIN CONTINUING TODAY?
Yes. Ipamorelin remains relevant to research involving ghrelin receptors, growth hormone regulation, digestive movement, metabolism, and peptide selectivity. Current attention also includes the quality and safety of compounded products, since clinical evidence remains limited and findings from animal studies do not establish safety or effectiveness in humans.